Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a cannabis oil study in untreatable advanced hepatocellular carcinoma
NL-OMON49322Phase 2Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- May 2021
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cannabis oil in hepatocellular carcinoma (HCC), sponsored by University Medical Center Groningen. Primary endpoint: Objective response rate at 6 months by RECIST and mRECIST. Started May 2021; status: recruiting.
02
Drugs
cannabis oil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NL-OMON49322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49322.